AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20825712 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon α‐2a 180 microg injection once a week in combination with ribavirin 800‐1200 mg/d for 48 weeks
Number of subjects: 140
Study 20825712 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon α‐2a 180 microg injection once a week in combination with ribavirin 800‐1200 mg/d for 72 weeks
Number of subjects: 140
Study 20825712 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon α‐2a for 48 weeks in subgroup A2
Number of subjects: 140
Study 20825712 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon α‐2a for 24 weeks in subgroup A1
Number of subjects: 140
Study 20825712 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon α‐2a for 48 weeks in subgroup B1
Number of subjects: 140
Study 20825712 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon α‐2a for 72 weeks in subgroup B2
Number of subjects: 140
Study 20825712 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon α‐2a for 72 weeks in group C1
Number of subjects: 140
Study 18094315 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (group B)
Number of subjects: 42
Study 18094315 — intervention group
Group type: COMPARATOR
Intervention: No intervention (group A)
Number of subjects: 42
Study 16398772 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine lignocaine (5 mL of 2% lignocaine)
Number of subjects: 200
Study 16398772 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (5 mL)
Number of subjects: 200
Study 14657763 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV‐1 RNA amplification assay
Number of subjects: 124
Study 14657763 — intervention group
Group type: EXPERIMENTAL
Intervention: PBMC microculture
Number of subjects: 124
Study 14657763 — intervention group
Group type: EXPERIMENTAL
Intervention: PBMC HIV‐1 DNA amplification assay
Number of subjects: 124
Study 14657763 — intervention group
Group type: EXPERIMENTAL
Intervention: RNA assay
Number of subjects: 124
Study 11019370 — intervention group
Group type: EXPERIMENTAL
Intervention: 5'-DFUR (600 mg/day for 2 years)
Number of subjects: 62
Study 11019370 — intervention group
Group type: COMPARATOR
Intervention: Control (no 5'-DFUR)
Number of subjects: 62
Study 8990730 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention starting at 3 months adjusted age
Number of subjects: 65
Study 8990730 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention starting at 12 months adjusted age
Number of subjects: 65
Study 1484176 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs), specifically sertraline
Number of subjects: 0
Study 1484176 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline, imipramine, and dothiepin
Number of subjects: 0
Study 3881629 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastectomy
Number of subjects: 41
Study 3881629 — intervention group
Group type: COMPARATOR
Intervention: Tumorectomy
Number of subjects: 41
Study 3881629 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastectomy and Tumorectomy
Number of subjects: 41
Study 29615088 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided needle release of the TCL plus corticosteroid injection (group A)
Number of subjects: 49
Study 29615088 — intervention group
Group type: COMPARATOR
Intervention: Single ultrasound-guided needle release of the TCL (group B)
Number of subjects: 49
Study 29615088 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 49
Study 27179112 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 293
Study 27179112 — intervention group
Group type: COMPARATOR
Intervention: No Cetuximab
Number of subjects: 293
Study 27179112 — intervention group
Group type: EXPERIMENTAL
Intervention: FCGR3A (rs396991)
Number of subjects: 293
Study 24899618 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischaemic preconditioning (IPC)
Number of subjects: 0
Study 24899618 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 22867978 — intervention group
Group type: EXPERIMENTAL
Intervention: Containers with an adapted sterilizing filter (Hyabak; Thea)
Number of subjects: 30
Study 22867978 — intervention group
Group type: COMPARATOR
Intervention: Conventional containers
Number of subjects: 30
Study 22867978 — intervention group
Group type: COMPARATOR
Intervention: In-patient conventional containers
Number of subjects: 30
Study 20945036 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone extract (80 mg daily for 4 months)
Number of subjects: 38
Study 20945036 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 18356795 — intervention group
Group type: EXPERIMENTAL
Intervention: Trigger point acupuncture
Number of subjects: 30
Study 18356795 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard acupuncture
Number of subjects: 30
Study 18356795 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 30
Study 16911252 — intervention group
Group type: EXPERIMENTAL
Intervention: Training (ten 5‐s contractions per day for 12 weeks)
Number of subjects: 29
Study 16911252 — intervention group
Group type: COMPARATOR
Intervention: Control (contralateral untrained muscle)
Number of subjects: 29
Study 12001756 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancies with PIH
Number of subjects: 37
Study 12001756 — intervention group
Group type: COMPARATOR
Intervention: Normal pregnancies
Number of subjects: 37
Study 10439987 — intervention group
Group type: EXPERIMENTAL
Intervention: Action research intervention (facilitating practice meetings and providing written feedback)
Number of subjects: 28
Study 10439987 — intervention group
Group type: COMPARATOR
Intervention: Control group (written feedback alone)
Number of subjects: 28
Study 7503080 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-hydroxyvitamin D3, 40 to 60 micrograms/d for 1 week
Number of subjects: 8
Study 7503080 — intervention group
Group type: COMPARATOR
Intervention: Postcontrol study after discontinuation of treatment
Number of subjects: 8
Study 2240530 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg orally the night before surgery and 20 mg intramuscularly 60 minutes before induction of anaesthesia
Number of subjects: 55
Study 2240530 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg orally the night before surgery and 400 mg orally 60 minutes before induction of anaesthesia
Number of subjects: 55
Study 2240530 — intervention group
Group type: COMPARATOR
Intervention: Control group (no famotidine or cimetidine)
Number of subjects: 55
Study 83189 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprinosine treatment
Number of subjects: 0
Study 83189 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 31549310 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperative parent-mediated therapy (CPMT)
Number of subjects: 34
Study 31549310 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity psychosocial intervention (LPI)
Number of subjects: 34
Study 31172338 — intervention group
Group type: COMPARATOR
Intervention: Intranasal dexmedetomidine
Number of subjects: 275
Study 31172338 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine with buccal midazolam
Number of subjects: 275
Study 28182446 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Self-Efficacy Questionnaire (SEQ-12)
Number of subjects: 0
Study 28182446 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-factor model of SEQ-12
Number of subjects: 0
Study 25812804 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg ondansetron
Number of subjects: 210
Study 25812804 — intervention group
Group type: COMPARATOR
Intervention: 5 ml normal saline (Control)
Number of subjects: 210
Study 23695174 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face interview
Number of subjects: 143
Study 23695174 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone delivery
Number of subjects: 143
Study 23695174 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face then telephone
Number of subjects: 143
Study 23695174 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone then face-to-face
Number of subjects: 143
Study 23695174 — intervention group
Group type: EXPERIMENTAL
Intervention: New scoring system for cognitive recovery
Number of subjects: 143
Study 23695174 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment at 3 days
Number of subjects: 143
Study 21384066 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-pharmacist team management
Number of subjects: 253
Study 21384066 — intervention group
Group type: COMPARATOR
Intervention: Physician(s) only management
Number of subjects: 253
Study 19602104 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-screw implants (G1)
Number of subjects: 34
Study 19602104 — intervention group
Group type: COMPARATOR
Intervention: Transpalatal arches (G2)
Number of subjects: 34
Study 17028992 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive behavioral stress management expressive supportive therapy (CBSM+) intervention plus a healthier lifestyles (HL) component
Number of subjects: 237
Study 17028992 — intervention group
Group type: COMPARATOR
Intervention: Individual educational/informational format plus HL
Number of subjects: 237
Study 10632913 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron 0.2 mg.kg‐1 up to 5 mg
Number of subjects: 71
Study 10632913 — intervention group
Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 71
Study 9162432 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose insulin (physiological concentration)
Number of subjects: 0
Study 9162432 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose insulin (physiological concentration)
Number of subjects: 0
Study 9162432 — intervention group
Group type: COMPARATOR
Intervention: Control (no insulin)
Number of subjects: 0
Study 1519121 — intervention group
Group type: EXPERIMENTAL
Intervention: Granuflex‐E (occlusive dressing)
Number of subjects: 10
Study 1519121 — intervention group
Group type: COMPARATOR
Intervention: tulle gras (semi‐open dressing)
Number of subjects: 10
Study 6523326 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamphenicol (500 mg three times daily for 7-14 days)
Number of subjects: 122
Study 6523326 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline (100 mg three times daily for 7-14 days)
Number of subjects: 122
Study 6523326 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamphenicol (in culture-negative group)
Number of subjects: 122
Study 6523326 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline (in culture-negative group)
Number of subjects: 122
Study 6523326 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 122
Study 30531832 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib (200 mg BID for 7 days of each 14‐day cycle) + FOLFIRI
Number of subjects: 130
Study 30531832 — intervention group
Group type: COMPARATOR
Intervention: Placebo + FOLFIRI
Number of subjects: 130
Study 30531832 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib + FOLFIRI
Number of subjects: 130
Study 30531832 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib
Number of subjects: 130
Study 30531832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 29535060 — intervention group
Group type: EXPERIMENTAL
Intervention: 22-gauge needle with suction
Number of subjects: 352
Study 29535060 — intervention group
Group type: EXPERIMENTAL
Intervention: 22-gauge needle without suction
Number of subjects: 352
Study 29535060 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-gauge needle with suction
Number of subjects: 352
Study 29535060 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-gauge needle without suction
Number of subjects: 352
Study 29535060 — intervention group
Group type: EXPERIMENTAL
Intervention: ROSE
Number of subjects: 352
Study 29535060 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-FNA
Number of subjects: 352
Study 29535060 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell block
Number of subjects: 352
Study 26694545 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP‐1 receptor antagonist exendin‐(9‐39)
Number of subjects: 6
Study 26694545 — intervention group
Group type: COMPARATOR
Intervention: Vehicle infusion
Number of subjects: 6
Study 26694545 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 pmol/kg/min of exendin‐(9‐39)
Number of subjects: 6
Study 26694545 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 pmol/kg/min of exendin‐(9‐39)
Number of subjects: 6
Study 24152055 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal Digital Assistant (PDA)
Number of subjects: 376
Study 24152055 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Disease Self-Management Program (CDSMP)
Number of subjects: 376
Study 24152055 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined PDA and CDSMP
Number of subjects: 376
Study 24152055 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 376
Study 22456303 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral solution of lesogaberan (100 mg)
Number of subjects: 57
Study 22456303 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified release (MR) capsules of lesogaberan (50% dissolution over 4 h)
Number of subjects: 57
Study 22456303 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified release (MR) capsules of lesogaberan (100% dissolution over 4 h)
Number of subjects: 57
Study 20152871 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise trial (90 min running at 68.8% of maximum oxygen uptake)
Number of subjects: 9
Study 20152871 — intervention group
Group type: COMPARATOR
Intervention: Control trial (no exercise)
Number of subjects: 9
Study 20152871 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise trial (90 min running)
Number of subjects: 9
Study 16860976 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean red ginseng (KRG) preparation (2 g/meal=6 g/day) for 12 weeks
Number of subjects: 19
Study 16860976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 16009907 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose interferon beta 1a
Number of subjects: 0
Study 16009907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16009907 — intervention group
Group type: EXPERIMENTAL
Intervention: MS relapses
Number of subjects: 0
Study 16009907 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable patients
Number of subjects: 0
Study 11850287 — intervention group
Group type: EXPERIMENTAL
Intervention: GW 420867X 50 mg
Number of subjects: 1000
Study 11850287 — intervention group
Group type: EXPERIMENTAL
Intervention: GW 420867X 100 mg
Number of subjects: 1000
Study 11850287 — intervention group
Group type: EXPERIMENTAL
Intervention: GW 420867X 200 mg
Number of subjects: 1000
Study 11850287 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 1000
Study 10420495 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLX) 40 mg or 60 mg per day
Number of subjects: 53
Study 10420495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 10420495 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (FLX) 20 mg per day
Number of subjects: 53
Study 7674813 — intervention group
Group type: EXPERIMENTAL
Intervention: Besipirdine hydrochloride (10, 20, 30, 40 mg bid for 2 days each, followed by 50 and 60 mg bid for 5 days each)
Number of subjects: 12
Study 7674813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2189040 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 cans/day of mackerel fillet in tomato pulp for 2 weeks
Number of subjects: 44
Study 2189040 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 cans/week of mackerel for 8 months
Number of subjects: 44
Study 2189040 — intervention group
Group type: COMPARATOR
Intervention: 2 cans/day of herring fillet in tomato pulp for 2 weeks
Number of subjects: 44
Study 31404539 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole chocolate bar (100g)
Number of subjects: 80
Study 31404539 — intervention group
Group type: COMPARATOR
Intervention: Segmented chocolate pieces (6 pieces)
Number of subjects: 80
Study 31404539 — intervention group
Group type: EXPERIMENTAL
Intervention: High chocolate specific appetite
Number of subjects: 80
Study 30242380 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of medical scribes during clinic visits
Number of subjects: 18
Study 26809247 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary fracture fixation with external fixation and defined secondary definitive treatment (DCO)
Number of subjects: 34
Study 26809247 — intervention group
Group type: COMPARATOR
Intervention: Primary reamed nailing (early total care)
Number of subjects: 34
Study 23461895 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-936557 (10 mg/kg) intravenously every other week
Number of subjects: 109
Study 23461895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 23461895 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-936557 (Cminss 108-235 μg/ml)
Number of subjects: 109
Study 23461895 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-936557
Number of subjects: 109
Study 22100823 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 5 μg
Number of subjects: 40
Study 22100823 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 10 μg
Number of subjects: 40
Study 22100823 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 25 μg
Number of subjects: 40
Study 22100823 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 0 μg
Number of subjects: 40
Study 20236906 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 0
Study 20236906 — intervention group
Group type: COMPARATOR
Intervention: Diode laser (980 nm) with scaling and root planing (SRP)
Number of subjects: 0
Study 20236906 — intervention group
Group type: COMPARATOR
Intervention: Nd:YAG laser (1,064 nm) with scaling and root planing (SRP)
Number of subjects: 0
Study 18036359 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 159
Study 18036359 — intervention group
Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 159
Study 16131708 — intervention group
Group type: EXPERIMENTAL
Intervention: Men (isometric muscle actions)
Number of subjects: 15
Study 16131708 — intervention group
Group type: EXPERIMENTAL
Intervention: Women (isometric muscle actions)
Number of subjects: 15
Study 16131708 — intervention group
Group type: EXPERIMENTAL
Intervention: Men (MMG mean power frequency vs. isometric torque)
Number of subjects: 15
Study 16131708 — intervention group
Group type: EXPERIMENTAL
Intervention: Women (MMG mean power frequency vs. isometric torque)
Number of subjects: 15
Study 12040649 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine needle aspiration cytology of fibroadenoma with multinucleated stromal giant cells
Number of subjects: 2
Study 12040649 — intervention group
Group type: EXPERIMENTAL
Intervention: Histologic examination of lumpectomy specimens
Number of subjects: 2
Study 10524660 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN) infusion (0.5 microg/kg/min for 20 min)
Number of subjects: 12
Study 10524660 — intervention group
Group type: COMPARATOR
Intervention: Control group (14 healthy subjects)
Number of subjects: 12
Study 7675964 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (0.2 mg)
Number of subjects: 10
Study 7675964 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 10
Study 2076408 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 0
Study 2076408 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine + Chlorthalidone
Number of subjects: 0
Study 6766733 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifluorothymidine (TFT)
Number of subjects: 0
Study 6766733 — intervention group
Group type: COMPARATOR
Intervention: Adenine arabinoside (ara‐A)
Number of subjects: 0
Study 31830835 — intervention group
Group type: EXPERIMENTAL
Intervention: Peri-conceptional progesterone treatment
Number of subjects: 0
Study 31830835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29741688 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise education and motivational interview program based on the stages of change model (SCM)
Number of subjects: 55
Study 29741688 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 55
Study 28802289 — intervention group
Group type: EXPERIMENTAL
Intervention: Home enteral nutrition (HEN)
Number of subjects: 60
Study 28802289 — intervention group
Group type: COMPARATOR
Intervention: Standard care only (control)
Number of subjects: 60
Study 25679364 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized screening and motivational intervention (ASSIST/MBIc)
Number of subjects: 458
Study 25679364 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-computerized screening and motivational intervention (ASSIST/MBIi)
Number of subjects: 458
Study 25679364 — intervention group
Group type: COMPARATOR
Intervention: Screening only (control)
Number of subjects: 458
Study 23989814 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Ravitch repair (group A)
Number of subjects: 31
Study 23989814 — intervention group
Group type: COMPARATOR
Intervention: Video-assisted thoracoscopic repair using metal stabilizers (group B)
Number of subjects: 31
Study 23989814 — intervention group
Group type: COMPARATOR
Intervention: Video-assisted thoracoscopic repair using absorbable stabilizers (group C)
Number of subjects: 31
Study 21145834 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate injection
Number of subjects: 89
Study 21145834 — intervention group
Group type: COMPARATOR
Intervention: Beta-blockers
Number of subjects: 89
Study 21145834 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 89
Study 19298364 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib 40 mg i.v. (Group Ia, n=54)
Number of subjects: 222
Study 19298364 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group Ib, n=56)
Number of subjects: 222
Study 19298364 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib 40 mg i.v. (Group IIa, n=57)
Number of subjects: 222
Study 19298364 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group IIb, n=55)
Number of subjects: 222
Study 19298364 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib 40 mg i.v. (Group Ia and IIa)
Number of subjects: 222